Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 3/20 | 0.52 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.46 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.46 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.44 |
| ▸ | PGAM1 | P18669 | 1/20 | 0.43 |
| ▸ | STAT3 | P40763 | 2/20 | 0.43 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18315257 | 0.88 | KEAP1 (0.50) | AXLKEAP1NFE2L2GLO1SLC40A1 | |
| SCHEMBL30304671 | 0.88 | KEAP1 (0.50) | AXLKEAP1NFE2L2GLO1SLC40A1 | |
| SCHEMBL31478916 | 0.87 | AXL (0.53) | AXLKEAP1NFE2L2GLO1SLC40A1 | |
| SCHEMBL3097960 | 0.87 | AXL (0.53) | AXLKEAP1NFE2L2GLO1SLC40A1 | |
| SCHEMBL3095654 | 0.87 | STAT3 (0.51) | KEAP1NFE2L2GLO1STAT3SCN9A | |
| SCHEMBL4779121 | 0.86 | KEAP1 (0.45) | AXLKEAP1NFE2L2GLO1SLC40A1 | |
| SCHEMBL4781379 | 0.85 | TSHR (0.46) | KEAP1NFE2L2STAT3SCN9AMEN1 | |
| SCHEMBL4780415 | 0.84 | MEN1 (0.57) | KEAP1NFE2L2PGRMEN1KMT2A | |
| SCHEMBL4780299 | 0.84 | CYP3A4 (0.41) | AXLCYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL4781526 | 0.84 | MEN1 (0.48) | STAT3SCN9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008008374-A2 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CHEMOCENTRYX, INC. (US) | 2008-01-17 | — | — | WO | claimed |
| US-20100234364-A1 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CHEMOCENTRYX, INC. | 2010-09-16 | — | — | US | disclosed |
| WO-2008008374-A2 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CHEMOCENTRYX, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234364-A1 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CCR2, CCR9, CCR1 | AXL 914/4885KEAP1 821/4885NFE2L2 2162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.